A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaMolecular therapeutics in pancreas cancerNovel agents for advanced pancreatic cancerSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTargeting the apoptosis pathway in hematologic malignanciesGetting TRAIL back on track for cancer therapyA multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastaticDual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotiniSerum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis.Recent treatment advances and novel therapies in pancreas cancer: a review.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapyCombination therapy in combating cancer.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Impact of diabetes type II and chronic inflammation on pancreatic cancer.Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis.Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.New targeted therapies in pancreatic cancer.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersTriptolide enhances the tumoricidal activity of TRAIL against renal cell carcinomaTargeting the insulin-like growth factor-1 receptor in human cancer.A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.Clinical targeting of the TNF and TNFR superfamiliesPhase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapyTherapeutic applications of TRAIL receptor agonists in cancer and beyond.Impact of targeting insulin-like growth factor signaling in head and neck cancers.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerPhysapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growthOptimum chemotherapy in the management of metastatic pancreatic cancerTargeted therapy in gastrointestinal malignancies.TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.
P2860
Q21129230-0C686FEB-CAAB-4458-87C5-EDD8AD97D58FQ26751709-5F57977F-0327-4B84-9840-FDC8D4DD9C4FQ26787087-5E432EFD-C5F4-413C-9835-DD7755409268Q26853171-8EBE49BE-BB0C-4715-AF42-7F4F92CAC36CQ26993238-B221F24D-6A1B-4132-A454-BA1C2913E80CQ27024422-CB711A23-415D-4F71-96A0-9A3E4B2570BFQ27027460-3F2CADB5-3CF8-4ACA-B917-124ABCB51F8DQ33406979-463D8629-F024-4745-A07F-59A9E398D9F3Q33414971-C8D446F2-7554-4410-B0B6-E5B2C07A4695Q33416585-89A0A814-AD70-4DB0-8AE5-0D2AF9854730Q33616917-DF19E377-5BDF-4063-9ECF-6F31B7AE7F3CQ33625168-1E546CDA-2828-4D5A-A55D-BB1276B147EBQ33632330-6084DBFE-BC14-4C48-AB2F-8424293FD8F6Q33710179-934AD8BA-3162-4FDF-8112-6DBBB526A7A8Q33914234-2170B27C-A472-402A-973F-FDCD9736CACAQ34110523-B3C95AF3-F350-449A-AC81-AA143AD602F0Q34336988-BB12E27C-B091-4DFD-833B-6279E784A273Q34532397-8AAD2C8B-B5DF-44FA-A0A1-2B7FBF2C91DCQ34557885-6BF8C7CB-B8E7-437A-AB80-DB4E99558890Q34669348-B1801D18-6387-4302-BB33-0CB31C3CA6B7Q35158520-41B31D35-53AE-4434-A797-9294451FA5C1Q35494483-02A20752-01CD-4BD8-A78E-C9F741E52D4EQ35604577-9A57669D-7242-4A0D-A2F4-1ED11D824E8DQ35609517-9C0DDE0E-062E-4DC6-B123-322767ABF7E0Q35651453-B8CFE5B0-AD25-4E31-B861-CDB344DB5925Q36384541-7F52D810-CA0F-4058-A5B0-6CC4E6BEC259Q36470781-C447ED2D-2936-41F4-BBDC-FDA2BEAC3B1BQ36708178-F5FEDDEA-5033-4D40-B0F7-FE3C2AAB6420Q36719024-655C4ED7-8894-4CD4-B420-A6B40FA7FD30Q36762882-F71EDB77-861C-4CA0-BF09-E13BFAE6F9A3Q36938811-D2171D70-C58B-486D-8A0D-235E50C6F75EQ37071019-D42835A4-3AEA-4D1F-90DD-4BD424E918DFQ37114025-7B2E667C-7D13-40D9-875E-5015F6BAAA1DQ37126107-395898D8-7DF0-44BB-B3D2-D493509C6626Q37138970-6CF06EC3-53E1-4D2F-BD01-F0329A35B25EQ37223809-D18C9713-974E-4A32-9F05-BC4433865A9CQ37617976-7BEE10BF-79F1-4A9E-9C86-B822C4916B50Q37702506-BC986A79-A616-4B3E-A67B-B16EB7B14826Q38204280-6A9B2CA7-6E5E-43AD-82B4-9F6438BBCCFFQ38234000-383DED7B-A6FD-4FE9-8A1F-340FC8F915D1
P2860
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@ast
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@en
type
label
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@ast
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@en
prefLabel
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@ast
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@en
P2093
P2860
P356
P1433
P1476
A randomized, placebo-controll ...... metastatic pancreatic cancer.
@en
P2093
C M Rocha-Lima
D A Richards
E G Feigal
H L Kindler
P2860
P304
P356
10.1093/ANNONC/MDS142
P577
2012-06-13T00:00:00Z